Who is sponsoring COPD-LT?

COPD-LT is sponsored by Augusta University.

What condition does COPD-LT study?

COPD-LT studies Chronic Obstructive Pulmonary Disease (COPD).

What drugs are being tested in COPD-LT?

Interventions: Tetrahydrobiopterin (BH4), Antioxidant Cocktail.

What is the status of COPD-LT?

COPD-LT is currently COMPLETED.

Last reviewed 2021-02-05 · How we verify

Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease (COPD-LT)

NCT02774226 Phase 2 COMPLETED Results posted

Chronic obstructive pulmonary disease (COPD) affects up to 14 million people and is among the top five leading causes of death worldwide. Although COPD is a disease of the lungs, recent evidence indicates that COPD is associated with multiple systemic consequences including vascular endothelial dysfunction. Recently, it has been suggested that more patients with COPD die from cardiovascular disease and coronary heart disease than of direct pulmonary complications. Examination of the mechanisms that contribute to a reduction nitric oxide (NO) bioavailability resulting in vascular endothelial dysfunction in patients with COPD are important as endothelial dysfunction has been indicated to be an independent predictor of future atherosclerotic cardiovascular disease and events.

Details

Lead sponsor	Augusta University
Phase	Phase 2
Status	COMPLETED
Enrolment	15
Start date	2015-09
Completion	2018-07-30

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Tetrahydrobiopterin (BH4)
Antioxidant Cocktail

Primary outcomes

Change in Flow Mediated Dilation — Change from Baseline and 12 weeks
Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and 12 weeks after treatment.

Countries

United States